ClinicalTrials.gg
Status unknownNCT04169178Updated May 1, 2020

Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status

A Phase 1 interventional study of HLX55 in Solid Tumor, Adult, sponsored by Henlix, Inc. Status unknown at 4 sites in Taiwan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-05-01.

Sponsored by Henlix, Inc · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
98
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

A mutilpe-center, open-label, dose-escalation Phase I clinical trial to evaluate the safety and the tolerability of HLX55 in patients with advanced solid tumors overexpressing/Mutation/Amplification cMET after failure of standard of care.

Read the detailed description

This study is an open-label and dose escalation study including dose finding stage and expansion stage.

In dosing finding stage, the study will precede in two phases, (i) a modified accelerated titration design 2A (ATD 2A) phase and (ii) a traditional 3+3 dose escalation phase aimed at exploring the safety and MTD of HLX55. Four dose levels are designed for HLX55 in this stage: 2.5, 5, 15, and 25 mg/kg/3 weeks. The 5 mg/kg/3 weeks will serve as the starting dose.

In the dose-expansion stage, three to five cohorts are planned, and different cohorts will evaluate the efficacy of HLX55 for potential indications. Maximum 20 patients will be accrued in each cohort.

02

Conditions studied

  • Solid Tumor, Adult
03

In context

Lead sponsor

Henlix, Inc is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Eligible patients must be 18-years of age or older (or per local regulations) and ≦75 years of age.
  2. For dose finding stage: patients with measurable or evaluable advanced or solid tumours who have failed standard therapy or for whom no standard therapy is available.
  3. For dose expansion stage: patients with measurable or evaluable advanced or metastatic solid tumors with confirmed c-MET mutations (MET exon 14 mutations) or amplifications (MET/CEP7 ratio ≥ 2.0 or MET ≥ 5.0 copies) or over-expression (immunohistochemistry [IHC] score ≥ 2+) and have failed standard therapy or for whom no standard therapy is available. Positive c-MET mutation/amplification/over-expression results should be available before the subject can receive HLX55.
  4. No prior therapy with MET-targeting biological agents (patients who have received prior therapy with a MET-targeting tyrosine kinase inhibitor [TKI] is allowed.)
  5. Must be able to supply adequate tumor tissue. (Adequate tumor material means (1) newly biopsied or archival tissue biopsied within 60 days before the first dosing, (2) Biopsy materials should be adequate for biomarker analysis (c-MET/Kras/EGFR).
  6. (ECOG) performance status of ≤ 2 at the time of study entry.
  7. Able to provide .
  8. A longer than three months.
  9. Adequate hematologic functions, as defined by ≥ 1500/mm3; a level ≥ 9 gm/dL; a count ≥ 100,000/mm3 and an ≤ 1.5.
  10. An adequate hepatic function defined by a total level ≤ 1.5 x of values (ULN); (AST) and alanine transaminase (ALT) levels ≤ 2.5 x of ULN or ≤ 5 x of ULN in known hepatic metastases or with primary hepatocellular carcinoma.
  11. Adequate renal function, as defined by the rate ≥ 50 mL/minute by Cockcroft-Gault formula. In patients with extreme body weights ( [BMI] \< 18.5 OR > 30) estimated (eGFR) ≥ 50ml/min calculated by Modification of Diet in Renal Disease (MDRD) formula is acceptable.
  12. Adequate cardiac function defined as (LVEF) ≥ 50% measured by either cardiac echo or multigated acquisition (MUGA) scan.
  13. At least 21days from prior cytotoxic chemotherapy, prior therapy with small molecule agents (or medical device) or radiotherapy, at least 28 days from prior immunotherapy, biological agents or prior major surgery and at least 14 days from prior hormonal therapy and minor surgery before infusion of first dose of HLX55.
  14. For patients with hepatocellular carcinoma, their score must be A.
  15. Able to be followed up as required by the study protocol.
  16. Female participants must have a negative pregnancy test at screening if of or be of non-childbearing potential.
  17. Female participants of childbearing potential and male partners with female partners of childbearing potential must agree to use 2 adequate barrier methods of during the study and for at least 180 days after last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. Patients who still have ≥ grade 2 toxicities from prior therapies.
  2. Concurrent unstable or uncontrolled medical conditions with either of the followings:

    • Active systemic infections requiring intravenous antibiotic use within 1 week;
    • Poorly controlled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥100 mmHg), or poor compliance with anti-hypertensive agents;
    • arrhythmia requiring anti-arrhythmia therapy, unstable angina pectoris, congestive heart failure (class III or IV of [NYHA]) or acute myocardial infarction within 6 months;
    • Uncontrolled diabetes or poor compliance with hypoglycemics defined by (HbA1c) ≥ 9.5%;
    • The presence of chronically unhealed wound or ulcers;
    • Uncontrolled hypercalcemia (defined as persistent Ionized (free) Calcium ≥ 6.5 mg/dl despite appropriate management.)
    • Other chronic diseases, which, in the opinion of the investigator, could compromise the safety of the patient or the integrity of the study.
  3. Newly-diagnosed or symptomatic (patients with a history of brain metastases must have received definitive surgery or radiotherapy, be clinically stable, and not taking for brain edema at least 14 days before infusion of the first dose of HLX55 can be allowed in the study). Anticonvulsants are allowed.
  4. Any concurrent other than basal cell carcinoma or carcinoma in situ of the cervix. (Patients with a previous malignancy but without evidence of disease for ≥ 3 years can participate).
  5. Known history of infection (HIV), virus carrier status (HBV surface antigen positive) and carrier (anti-HCV antibody positive).
  6. The patient is the investigator, sub-investigator or anyone directly involved in the conduct of the study.
  7. History or current evidence of any condition or disease that could confound the results of the study or, in the opinion of Investigator(s), is not in the best interest of the patient to participate.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
98 participants (estimated)

Study arms

  • Experimental
    HLX55, dose finding stage, advanced solid tumor

    Participants will receive HLX55 at assign dose level, e.g. 2.5, 5, 15 and 25 mg/kg every three weeks followed by a 21-day DLT observation period.

    Drug: HLX55

  • Experimental
    HLX55, dose expansion stage, gastric cancer

    Participants diagnosed with gastric cancer with will receive HLX55 in recommended phase 2 dose (RP2D) every three weeks.

    Drug: HLX55

  • Experimental
    HLX55, dose expansion stage, NSCLC

    Participants diagnosed with non-small cell lung cancer (NSCLC) with will receive HLX55 in RP2D every three weeks.

    Drug: HLX55

  • Experimental
    HLX55, dose expansion stage, colorectal cancer

    Participants diagnosed with colorectal cancer (CRC) with will receive HLX55 in RP2D every three weeks.

    Drug: HLX55

  • Experimental
    HLX55, dose expansion stage, other solid cancer

    Participants diagnosed with other solid cancer with will receive HLX55 in RP2D every three weeks.

    Drug: HLX55

Interventions

  • DrugHLX55

    A humanized IgG2 monoclonal antibody targeting tyrosine-protein kinase MET (c-MET)

    Also known as: HLX55 monoclonal antibody for Injection

06

What researchers measure

Primary outcomes

  1. Dose finding stage-safety

    Numbers and percentage of patients with adverse events (AEs).

    Time frame: Up to 2 years

  2. Dose finding stage-MTD or RP2D

    The maximum tolerated dose and recommended phase 2 dose (RP2D) of HLX55.

    Time frame: Up to 2 years

  3. Dose expansion stage-safety

    Numbers and percentage of patients with adverse events (AEs).

    Time frame: Up to 2 years

  4. Dose expansion stage-efficacy

    Disease control rate (DCR).

    Time frame: Up to 2 years

  5. Dose expansion stage-efficacy

    Overall response rate (ORR).

    Time frame: Up to 2 years

  6. Dose expansion stage-efficacy

    Duration of response (DOR).

    Time frame: Up to 2 years

Secondary outcomes

  1. Dose finding stage and dose expansion stage-PK profile

    PK profile of HLX55 including maximum concentration (Cmax), minimum concentration (Cmin), area under concentration (AUC0-tau), half-life (T1/2), clearance (CL) rate and the volume of distribution at steady state (Vss) at different doses.

    Time frame: Through study completion, up to 2 years.

  2. Dose finding stage and dose expansion stage-serum HGF levels

    Changes in serum HGF levels before and at different time-points after HLX55 treatment.

    Time frame: Cycle 1 to 3 (each cycle is 21 days)

  3. Dose finding stage and dose expansion stage-immunogenicity

    The presence and percentage of anti-HLX55 antibody-positive patients (immunogenicity) by measurement of anti-HLX55 antibodies in serum.

    Time frame: Up to 2 years

Other outcomes

  1. Dose finding stage and dose expansion stage-cMET status

    Relationship between levels or status of c-MET mutations/overexpression/amplification, EGFR mutation and KRAS mutation

    Time frame: up to 3 cycles (each cycle is 21 days)

07

Study locations

4 of 4 sites recruiting
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
    Recruiting
    • Wu-Chou Su · Contact886-6-2353535
  • Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare
    Taipei county, 235, Taiwan
    Recruiting
    • Tsu-Yi Chao · Contact886-2-22490088
  • Tri-Service General Hospital
    Taipei, 114, Taiwan
    Recruiting
    • Ching-Liang Ho · Contact886-2-8792-7211
  • Taipei Minicipal Wangfang Hospital
    Taipei, 116, Taiwan
    Recruiting
    • Chia Lun Chang · Contact886-2-2930-7930
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2020 (actual). Primary completion is estimated for Dec 2022, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2019
First posted
Nov 19, 2019
StartActual
Mar 3, 2020
Primary completionEst.
Dec 2022
CompletionEst.
Dec 2022
Last update
May 1, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04169178
Lead sponsor
Henlix, Inc
Responsible party
Sponsor
First posted
Nov 19, 2019
Start date
Mar 3, 2020
Primary completion
Dec 2022 (estimated)
Completion
Dec 2022 (estimated)
Last update
May 1, 2020

Study contacts

PeiZhi Lu
Contact
plu@henlix.com
+886-2-792-7927 ext. 107
Tsu-Yi Chao, MD. PhD.
principal investigator · Shuang Ho Hospital,Ministry of Health and Welfare, Taipei, Taiwan
Ching-Liang Ho, MD
principal investigator · Tri-Service General Hospital, Taipei, Taiwan
Wu-Chou Su, MD. PhD.
principal investigator · National Cheng Kung University Hospital, Tainan, Taiwan
Chia-Lun Chang, MD
principal investigator · Taipei Municipal Wanfang Hospital, Taipei, Taiwan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion